Katherine Matthay, MD

Recall Professor
M_PEDS-ONCOLOGY

Dr. Matthay is a professor in the Pediatric Department of the UCSF School of Medicine and the leader of the Pediatric Malignancies Program in the Helen Diller Family Comprehensive Cancer Center. For more than 25 years, she has focused on translational research in neuroblastoma. In Morocco, Dr. Matthay is working with collaborators on the development of a high-risk neuroblastoma protocol. She has participated for many years on the International Society of Paediatric Oncology (SIOP) committee, Pediatric Oncology in Developing Countries committee. She was also the North American president of SIOP for many years. She leads the Global Neuroblastoma Network, a weekly online tumor board for resource-limited countries and has mentored student and resident projects in Africa and Central America. In addition, she has conducted focused one week teaching programs for residents, fellows, and faculty in pediatric oncology in Haiti and Tanzania.

Publications

International neuroblastoma risk group consortium: a model of a networking for rare cancers.

Journal of the National Cancer Institute

Cohn SL, London WB, Schleiermacher G, Moreno L, Ambros IM, Ambros PF, Bagatell R, Popovicmd MB, Beiske KH, Berthold F, Birz S, Brisse HJ, Brodeur GM, Brock PR, Burchill S, Eggert A, Federico SM, Fischer M, Furner BT, Hero B, Machin D, Kamijo T, Matthay KK, Nakagawara A, Naranjo A, Pötschger U, Valteau-Couanet D, Watkins MT, Irwin MS, Volchenboum SL, Park JR, Pearson ADJ

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG, Jonus HC, Shamirian A, Crowley M, Goodarzian F, Acharya PT, Pawel B, Erbe AK, Shahi A, Zaborek J, Kennedy E, Asgharzadeh S, Villablanca JG, Pinto N, Weiss BD, Mosse YP, Desai AV, Macy ME, Granger M, Vo KT, Sondel PM, Matthay KK, Park JR, Goldsmith KC

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.

Nature medicine

Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Moss? YP

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL

Phase 2 Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Dubois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith KC, Granger M, Weiss B, Park JR, Macy ME, Cohn SL, Yanik GA, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Clinical cancer research : an official journal of the American Association for Cancer Research

Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.

Clinical cancer research : an official journal of the American Association for Cancer Research

Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC

Neuroblastoma.

Nature reviews. Disease primers

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK

Reply to N.-K.V. Cheung et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Matthay KK, London WB, Maris J, Adamson PC, Park JR

The International Neuroblastoma Risk Groups (INRG): a preliminary report.

European journal of cancer (Oxford, England : 1990)

Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B, Dicks-Mireaux C, Frappaz D, Haase GM, Haber M, Jones DR, Joshi VV, Kaneko M, Kemshead JT, Kogner P, Lee RE, Matthay KK, Michon JM, Monclair R, Roald BR, Seeger RC, Shaw PJ, Shuster JJ

Ewing's sarcoma of the mandible.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery

Langman AW, Kaplan MJ, Matthay K